① What are the highlights of the AI technology company Nobikan submitting its listing application? ② Jiangsu Hengrui Pharmaceuticals and several other companies have started their IPOs; how was the last feedback?
On May 18, Financial Link reported (Editor Feng Yi) that Financial Link brings you weekly news on new Hong Kong stocks.
As of the time of this report, this week (from May 12 to May 18), two companies have submitted their applications, and three companies have passed the hearing; in addition, four companies have opened for subscriptions, and one new stock has been listed.
First, let’s look at the submitted applications. A total of two companies submitted their listing applications this week:
1) On May 12, Oriental Yanmei (Chengdu) Biotechnology Co., Ltd. submitted its application to the Hong Kong Stock Exchange, with Jianyin International as its exclusive sponsor.
According to the prospectus, Yanmei Biotechnology is a medical health company established in 2016, mainly engaged in the research, development, production, and commercialization of regenerative medicine medical instruments and special medical foods. As of May 5, 2025, the company has 13 main candidate products for regenerative medical materials injections (all classified as Class III medical instruments), including the core product XH301 and the candidate product XH321 used for the treatment of female stress urinary incontinence. Among the 13 candidate products, two have entered the registration review stage.
From a financial perspective, in 2023 and 2024, Yanmei Biotechnology's revenues were 12.882 million yuan and 14.52 million yuan, respectively; during the same period, the annual loss and total comprehensive loss amounted to 63.501 million yuan and 69.383 million yuan.
2) On May 14, Nobikan AI Technology (Chengdu) Co., Ltd. submitted its application to the Hong Kong Stock Exchange, with China International Capital Corporation as the exclusive sponsor.
The prospectus shows that Nobikang focuses on advanced technologies such as AI and Digital Twin, with industrial applications in areas like AI + Transportation, AI + Energy, and AI + Urban Governance. The company mainly provides integrated software and hardware solutions based on comprehensive AI industry models. The self-developed NBK-INTARI AI platform empowers clients in the fields of transportation, energy, and urban governance by achieving intelligent monitoring, detection, and operations. According to Zheshang Consulting, in terms of revenue for 2023, the company ranks as the seventh largest AI + Detection and Monitoring solution provider in China's rail transit industry.
Financially, in the years 2022, 2023, and 2024, Nobikang achieved revenues of approximately 0.253 billion yuan, 0.364 billion yuan, and 0.403 billion yuan respectively; during the same period, net profits were 63.161 million yuan, 88.566 million yuan, and approximately 0.115 billion yuan.
Looking at the listings, three companies passed the listing hearing this week:
1) May 12, $Mirxes Holding Company Limited (810521.HK)$ passed the Main Board listing hearing of the Hong Kong Stock Exchange, with China International Capital Corporation and Jianyin International as its joint sponsors.
The prospectus shows that Mirxes Holding Company Limited was established in 2014 and is a micro RNA ("miRNA") technology company headquartered in Singapore. The company currently has one core product (GASTROClearTM), two other commercialized products (LUNGClearTM and FortitudeTM), and six candidate products in the preclinical stage. According to Frost & Sullivan, the core product GASTROClearTM is the first and only molecular diagnostic IVD product approved for gastric cancer screening globally.
In terms of finances, Mirxes Holding Company is expected to achieve revenues of approximately 17.759 million USD, 24.185 million USD, and 20.2827 million USD in 2022, 2023, and 2024 respectively, with gross profits of approximately 9.3264 million USD, 13.582 million USD, and 8.887 million USD during the same period.
According to the announcement, Mirxes Holding Company Limited (02629.HK) will conduct its public offering from May 15 to May 20, 2025, proposing a global issuance of 46.62 million shares, with 10% for the Hong Kong offering and 90% for international offering; the offering price will be HKD 23.30 per share; each lot is 100 shares, and it is expected that the H shares will start trading on the Stock Exchange at 9:00 AM on May 23, 2025 (Friday).
On May 15, $Shouhui Tech Ltd (810555.HK)$ Through the Main Board listing hearing on the Hong Kong Stock Exchange, Huatai International and China International Capital Corporation are its joint sponsors.
According to the prospectus, the company is an intermediary services provider for life insurance in China, committed to providing insurance service solutions online for policyholders and insured through its life insurance trading and service platform. In 2023, based on the total premiums of the life insurance intermediary market in China, the company ranked eighth with a market share of 2.9%.
In terms of finances, the revenue of Handreturn Group for 2022, 2023, and 2024 was approximately 0.806 billion yuan, 1.634 billion yuan, and 1.387 billion yuan, respectively; during the same period, the yearly profits were approximately 0.131 billion yuan, -0.356 billion yuan, and -0.136 billion yuan.
On May 16, Meta Light Inc. passed the Main Board listing hearing on the Hong Kong Stock Exchange, with China International Capital Corporation as its exclusive sponsor.
According to the prospectus, the company is a leading provider of time-series data intelligent services in the public transport sector in China. It is the largest real-time public transport information service platform in 2023 in terms of urban coverage in China. Its mobile application attracts millions of active users and generates a stable mobile advertising revenue base through extensive audience coverage.
In terms of finances, Yuan Guang Technology's revenue for 2022, 2023, and 2024 is projected to be 0.135 billion yuan, 0.174 billion yuan, and 0.206 billion yuan, respectively; with gross profits of 98.8 million yuan, 0.133 billion yuan, and 0.157 billion yuan; and gross margins of 73%, 76.3%, and 76.4%. During the same period, adjusted net profits are expected to be 9.81 million yuan, 46.5 million yuan, and 54.22 million yuan, respectively.
In addition, two other companies will be listed on the Hong Kong Stock Exchange.
1）$CATL (03750.HK)$The public offering will take place from May 12 to 15. Approximately 0.118 billion shares of H shares will be globally offered, with 8.8421 million shares available for sale in Hong Kong and about 0.109 billion shares for international sale, planning to list on the Hong Kong Stock Exchange on May 20.
According to the announcement, Contemporary Amperex Technology's offering price is set at 263.00 Hong Kong dollars, and the public offering is also quite hot, with a subscription ratio of nearly 120 times. It is expected to be listed on the Hong Kong Stock Exchange on May 20.
2） $HENGRUI PHARMA (01276.HK)$ Going public from May 15 to May 20, 2025, with a planned global issuance of 0.2245 billion H shares, of which 5.5% is allocated for Hong Kong sales and 94.5% for international sales; the offering price will not exceed HKD 44.05 per share and is currently expected not to be lower than HKD 41.45 per share; each lot is 200 shares of H stock, and H shares are expected to be traded on the Stock Exchange on May 23, 2025.
For details, please click to view >> Beginner's Guide: How to subscribe for new stocks? 5 important days to remember.Remember.
Use Futu to apply for new shares, truly 0 interest, 0 handling fees, 0 cash subscription*, dark pool trading gets ahead of others.Come and experience it >>
Editor/Somer
